Hemodynamic effects of a new inotropic compound, PST-2744, in dogs with chronic ischemic heart failure
Journal of Cardiovascular Pharmacology, ISSN: 0160-2446, Vol: 42, Issue: 2, Page: 169-173
2003
- 29Citations
- 16Captures
- 3Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations29
- Citation Indexes29
- 29
- CrossRef21
- Captures16
- Readers16
- 16
- Mentions3
- References3
- Wikipedia3
Article Description
Inotropic agents for acute decompensated heart failure are associated with a lack of efficacy or increased mortality. New compounds are needed to support patients with acute exacerbations of heart failure. This study examined the hemodynamic effects of a new inotropic agent (PST-2744) in dogs with chronic ischemic heart failure. Eight mongrel dogs at low risk for postmyocardial infarction (MI) sudden death entered the protocol. Dogs were studied after ischemic left ventricular dysfunction was induced by repeated injections of latex microspheres into the circumflex artery until the ejection fraction reached 35%. Hemodynamic parameters were measured at baseline and peak drug effect (PST-2744 5 μg·kgmin). In 5 animals, PST-2744 effects were compared with dobutamine. Heart rates, PR intervals and QT intervals were unchanged following PST-2744 administration. PST-2744 increased contractility (+dP/dt) by 56% from 1881 ± 282 mm Hg/s to 2939 ± 734 mm Hg/s (P < 0.01). The inotropic effect of PST-2744 was equal to that produced by 5-μg·kg·min dobutamine (56% increase in +dP/dt), but peak heart rates were significantly higher with dobutamine (129 ± 24 bpm PST-2744 versus 160 ± 6 bpm 5-μg·kg·min dobutamine, P < 0.002). No arrhythmias or conduction delays were seen with either compound. PST-2744 is an effective inotropic agent without positive chronotropic effect in subjects with stable moderate left ventricular dysfunction.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0041302190&origin=inward; http://dx.doi.org/10.1097/00005344-200308000-00003; http://www.ncbi.nlm.nih.gov/pubmed/12883318; http://journals.lww.com/00005344-200308000-00003; https://dx.doi.org/10.1097/00005344-200308000-00003; https://journals.lww.com/cardiovascularpharm/Fulltext/2003/08000/Hemodynamic_Effects_of_a_New_Inotropic_Compound,.3.aspx
Ovid Technologies (Wolters Kluwer Health)
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know